文献速递肝病消化道肿瘤与早癌

CDK4/6抑制剂联合疗法治疗RB1完整型肝细胞癌

Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
PubMed 文献 · Hepatology · 2021-08-25

该研究探讨合成CDK4/6抑制剂对RB1完整型肝细胞癌的治疗潜力。在Trp53-/-小鼠肝脏中缺失全部Rb家族成员可形成类似人肝细胞癌的肿瘤,重新表达RB1使肿瘤对palbociclib敏感。筛选发现IKKβ抑制剂Bay 11-7082可增强RB7LP疗效,palbociclib联合Bay 11-7082对肝母细胞瘤和肝细胞癌的治疗效果显著优于单药。

要点

  • RB1完整型肝细胞癌可能从CDK4/6抑制剂治疗中获益
  • palbociclib联合Bay 11-7082较单药显著增强抗肿瘤效果
  • 联合激酶抑制剂可拓展CDK4/6抑制剂在RB1完整型肿瘤中的应用

核心结论

  • CDK4/6抑制剂与适当激酶抑制剂联合,有潜力治疗包括肝细胞癌在内的多种RB1完整型癌症。

研究设计与样本

  • 在Trp53-/-小鼠肝脏中缺失全部Rb家族成员建立肝肿瘤模型,并重新表达RB1以测试palbociclib敏感性。
  • 将不可磷酸化型RB1(RB7LP)导入多种肝肿瘤细胞系,并筛选增强RB7LP疗效的化合物。

主要发现

  • Trp53-/-小鼠肝脏缺失全部Rb家族成员可形成类似人肝细胞癌的肝肿瘤。
  • 重新表达RB1使这些肿瘤对CDK4/6抑制剂palbociclib敏感。
  • RB7LP表达与palbociclib处理均增强IKKα/β磷酸化及NF-κB活化。
  • palbociclib联合Bay 11-7082对肝母细胞瘤和肝细胞癌的治疗效果显著优于单药。
  • 阻断IKK-NF-κB或AKT通路增强palbociclib对RB1完整型KRAS突变肺癌和结肠癌的效果。

临床怎么用

  • 对于RB1完整型肝细胞癌,可考虑CDK4/6抑制剂联合IKKβ抑制剂等激酶抑制剂的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Synthetic cyclin-dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy. APPROACH AND RESULTS: Loss of all Rb family members in transformation related protein 53 (Trp53)-/- mouse liver resulted in liver tumor reminiscent of human HCC, and re-expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11-7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF-κB activation. Combination therapy using palbociclib with Bay 11-7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK-NF-κB or AKT pathway enhanced effects of palbociclib on RB1-intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers. CONCLUSIONS: In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sheng J, Kohno S, Okada N, et al. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy. Hepatology. 2021. PMID: 33931882. doi:10.1002/hep.31872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。